A BILL 
To amend title XXVII of the Public Health Service Act, 
the Internal Revenue Code of 1986, and the Employee 
Retirement Income Security Act of 1974 to establish 
requirements with respect to cost-sharing for certain in-
sulin products, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Affordable Insulin Now 
4
Act’’. 
5
23:20 Mar 02, 2022
H6833
2 
•HR 6833 IH
SEC. 2. REQUIREMENTS WITH RESPECT TO COST-SHARING 
1
FOR INSULIN PRODUCTS. 
2
(a) PHSA.—Part D of title XXVII of the Public 
3
Health Service Act (42 U.S.C. 300gg–111 et seq.) is 
4
amended by adding at the end the following new section: 
5
‘‘SEC. 2799A–11. REQUIREMENTS WITH RESPECT TO COST- 
6
SHARING FOR CERTAIN INSULIN PRODUCTS. 
7
‘‘(a) IN GENERAL.—For plan years beginning on or 
8
after January 1, 2023, a group health plan or health in-
9
surance issuer offering group or individual health insur-
10
ance coverage shall provide coverage of selected insulin 
11
products, and with respect to such products, shall not— 
12
‘‘(1) apply any deductible; or 
13
‘‘(2) impose any cost-sharing in excess of the 
14
lesser of, per 30-day supply— 
15
‘‘(A) $35; or 
16
‘‘(B) the amount equal to 25 percent of 
17
the negotiated price of the selected insulin prod-
18
uct net of all price concessions received by or on 
19
behalf of the plan or coverage, including price 
20
concessions received by or on behalf of third- 
21
party entities providing services to the plan or 
22
coverage, such as pharmacy benefit manage-
23
ment services. 
24
‘‘(b) DEFINITIONS.—In this section: 
25
23:20 Mar 02, 2022
H6833
3 
•HR 6833 IH
‘‘(1) SELECTED INSULIN PRODUCTS.—The term 
1
‘selected insulin products’ means at least one of each 
2
dosage form (such as vial, pump, or inhaler dosage 
3
forms) of each different type (such as rapid-acting, 
4
short-acting, intermediate-acting, long-acting, ultra 
5
long-acting, and premixed) of insulin (as defined 
6
below), when available, as selected by the group 
7
health plan or health insurance issuer. 
8
‘‘(2) INSULIN
DEFINED.—The term ‘insulin’ 
9
means insulin that is licensed under subsection (a) 
10
or (k) of section 351 and continues to be marketed 
11
under such section, including any insulin product 
12
that has been deemed to be licensed under section 
13
351(a) pursuant to section 7002(e)(4) of the Bio-
14
logics Price Competition and Innovation Act of 2009 
15
and continues to be marketed pursuant to such li-
16
censure. 
17
‘‘(c) OUT-OF-NETWORK
PROVIDERS.—Nothing in 
18
this section requires a plan or issuer that has a network 
19
of providers to provide benefits for selected insulin prod-
20
ucts described in this section that are delivered by an out- 
21
of-network provider, or precludes a plan or issuer that has 
22
a network of providers from imposing higher cost-sharing 
23
than the levels specified in subsection (a) for selected insu-
24
23:20 Mar 02, 2022
H6833
4 
•HR 6833 IH
lin products described in this section that are delivered 
1
by an out-of-network provider. 
2
‘‘(d) RULE OF CONSTRUCTION.—Subsection (a) shall 
3
not be construed to require coverage of, or prevent a group 
4
health plan or health insurance coverage from imposing 
5
cost-sharing other than the levels specified in subsection 
6
(a) on, insulin products that are not selected insulin prod-
7
ucts, to the extent that such coverage is not otherwise re-
8
quired and such cost-sharing is otherwise permitted under 
9
Federal and applicable State law. 
10
‘‘(e) APPLICATION
OF
COST-SHARING
TOWARDS 
11
DEDUCTIBLES
AND OUT-OF-POCKET MAXIMUMS.—Any 
12
cost-sharing payments made pursuant to subsection (a)(2) 
13
shall be counted toward any deductible or out-of-pocket 
14
maximum that applies under the plan or coverage.’’. 
15
(b) IRC.— 
16
(1) IN
GENERAL.—Subchapter B of chapter 
17
100 of the Internal Revenue Code of 1986 is amend-
18
ed by adding at the end the following new section: 
19
‘‘SEC. 9826. REQUIREMENTS WITH RESPECT TO COST-SHAR-
20
ING FOR CERTAIN INSULIN PRODUCTS. 
21
‘‘(a) IN GENERAL.—For plan years beginning on or 
22
after January 1, 2023, a group health plan shall provide 
23
coverage of selected insulin products, and with respect to 
24
such products, shall not— 
25
23:20 Mar 02, 2022
H6833
5 
•HR 6833 IH
‘‘(1) apply any deductible; or 
1
‘‘(2) impose any cost-sharing in excess of the 
2
lesser of, per 30-day supply— 
3
‘‘(A) $35; or 
4
‘‘(B) the amount equal to 25 percent of 
5
the negotiated price of the selected insulin prod-
6
uct net of all price concessions received by or on 
7
behalf of the plan, including price concessions 
8
received by or on behalf of third-party entities 
9
providing services to the plan, such as phar-
10
macy benefit management services. 
11
‘‘(b) DEFINITIONS.—In this section: 
12
‘‘(1) SELECTED INSULIN PRODUCTS.—The term 
13
‘selected insulin products’ means at least one of each 
14
dosage form (such as vial, pump, or inhaler dosage 
15
forms) of each different type (such as rapid-acting, 
16
short-acting, intermediate-acting, long-acting, ultra 
17
long-acting, and premixed) of insulin (as defined 
18
below), when available, as selected by the group 
19
health plan. 
20
‘‘(2) INSULIN
DEFINED.—The term ‘insulin’ 
21
means insulin that is licensed under subsection (a) 
22
or (k) of section 351 of the Public Health Service 
23
Act (42 U.S.C. 262) and continues to be marketed 
24
under such section, including any insulin product 
25
23:20 Mar 02, 2022
H6833
6 
•HR 6833 IH
that has been deemed to be licensed under section 
1
351(a) of such Act pursuant to section 7002(e)(4) 
2
of the Biologics Price Competition and Innovation 
3
Act of 2009 (Public Law 111–148) and continues to 
4
be marketed pursuant to such licensure. 
5
‘‘(c) OUT-OF-NETWORK
PROVIDERS.—Nothing in 
6
this section requires a plan that has a network of providers 
7
to provide benefits for selected insulin products described 
8
in this section that are delivered by an out-of-network pro-
9
vider, or precludes a plan that has a network of providers 
10
from imposing higher cost-sharing than the levels specified 
11
in subsection (a) for selected insulin products described 
12
in this section that are delivered by an out-of-network pro-
13
vider. 
14
‘‘(d) RULE OF CONSTRUCTION.—Subsection (a) shall 
15
not be construed to require coverage of, or prevent a group 
16
health plan from imposing cost-sharing other than the lev-
17
els specified in subsection (a) on, insulin products that are 
18
not selected insulin products, to the extent that such cov-
19
erage is not otherwise required and such cost-sharing is 
20
otherwise permitted under Federal and applicable State 
21
law. 
22
‘‘(e) APPLICATION
OF
COST-SHARING
TOWARDS 
23
DEDUCTIBLES
AND OUT-OF-POCKET MAXIMUMS.—Any 
24
cost-sharing payments made pursuant to subsection (a)(2) 
25
23:20 Mar 02, 2022
H6833
7 
•HR 6833 IH
shall be counted toward any deductible or out-of-pocket 
1
maximum that applies under the plan.’’. 
2
(2) CLERICAL AMENDMENT.—The table of sec-
3
tions for subchapter B of chapter 100 of the Inter-
4
nal Revenue Code of 1986 is amended by adding at 
5
the end the following new item: 
6
‘‘Sec. 9826. Requirements with respect to cost-sharing for certain insulin prod-
ucts.’’. 
(c) ERISA.— 
7
(1) IN GENERAL.—Subpart B of part 7 of sub-
8
title B of title I of the Employee Retirement Income 
9
Security Act of 1974 (29 U.S.C. 1185 et seq.) is 
10
amended by adding at the end the following: 
11
‘‘SEC. 726. REQUIREMENTS WITH RESPECT TO COST-SHAR-
12
ING FOR CERTAIN INSULIN PRODUCTS. 
13
‘‘(a) IN GENERAL.—For plan years beginning on or 
14
after January 1, 2023, a group health plan or health in-
15
surance issuer offering group health insurance coverage 
16
shall provide coverage of selected insulin products, and 
17
with respect to such products, shall not— 
18
‘‘(1) apply any deductible; or 
19
‘‘(2) impose any cost-sharing in excess of the 
20
lesser of, per 30-day supply— 
21
‘‘(A) $35; or 
22
‘‘(B) the amount equal to 25 percent of 
23
the negotiated price of the selected insulin prod-
24
23:20 Mar 02, 2022
H6833
8 
•HR 6833 IH
uct net of all price concessions received by or on 
1
behalf of the plan or coverage, including price 
2
concessions received by or on behalf of third- 
3
party entities providing services to the plan or 
4
coverage, such as pharmacy benefit manage-
5
ment services. 
6
‘‘(b) DEFINITIONS.—In this section: 
7
‘‘(1) SELECTED INSULIN PRODUCTS.—The term 
8
‘selected insulin products’ means at least one of each 
9
dosage form (such as vial, pump, or inhaler dosage 
10
forms) of each different type (such as rapid-acting, 
11
short-acting, intermediate-acting, long-acting, ultra 
12
long-acting, and premixed) of insulin (as defined 
13
below), when available, as selected by the group 
14
health plan or health insurance issuer. 
15
‘‘(2) INSULIN
DEFINED.—The term ‘insulin’ 
16
means insulin that is licensed under subsection (a) 
17
or (k) of section 351 of the Public Health Service 
18
Act (42 U.S.C. 262) and continues to be marketed 
19
under such section, including any insulin product 
20
that has been deemed to be licensed under section 
21
351(a) of such Act pursuant to section 7002(e)(4) 
22
of the Biologics Price Competition and Innovation 
23
Act of 2009 (Public Law 111–148) and continues to 
24
be marketed pursuant to such licensure. 
25
23:20 Mar 02, 2022
H6833
9 
•HR 6833 IH
‘‘(c) OUT-OF-NETWORK
PROVIDERS.—Nothing in 
1
this section requires a plan or issuer that has a network 
2
of providers to provide benefits for selected insulin prod-
3
ucts described in this section that are delivered by an out- 
4
of-network provider, or precludes a plan or issuer that has 
5
a network of providers from imposing higher cost-sharing 
6
than the levels specified in subsection (a) for selected insu-
7
lin products described in this section that are delivered 
8
by an out-of-network provider. 
9
‘‘(d) RULE OF CONSTRUCTION.—Subsection (a) shall 
10
not be construed to require coverage of, or prevent a group 
11
health plan or health insurance coverage from imposing 
12
cost-sharing other than the levels specified in subsection 
13
(a) on, insulin products that are not selected insulin prod-
14
ucts, to the extent that such coverage is not otherwise re-
15
quired and such cost-sharing is otherwise permitted under 
16
Federal and applicable State law. 
17
‘‘(e) APPLICATION
OF
COST-SHARING
TOWARDS 
18
DEDUCTIBLES
AND OUT-OF-POCKET MAXIMUMS.—Any 
19
cost-sharing payments made pursuant to subsection (a)(2) 
20
shall be counted toward any deductible or out-of-pocket 
21
maximum that applies under the plan or coverage.’’. 
22
(2) CLERICAL AMENDMENT.—The table of con-
23
tents in section 1 of the Employee Retirement In-
24
come Security Act of 1974 (29 U.S.C. 1001 et seq.) 
25
23:20 Mar 02, 2022
H6833
10 
•HR 6833 IH
is amended by inserting after the item relating to 
1
section 725 the following: 
2
‘‘Sec. 726. Requirements with respect to cost-sharing for certain insulin prod-
ucts.’’. 
(d) NO EFFECT ON OTHER COST-SHARING.—Section 
3
1302(d)(2) of the Patient Protection and Affordable Care 
4
Act (42 U.S.C. 18022(d)(2)) is amended by adding at the 
5
end the following new subparagraph: 
6
‘‘(D) SPECIAL RULE RELATING TO INSU-
7
LIN COVERAGE.—The exemption of coverage of 
8
selected insulin products (as defined in section 
9
2799A–11(b) of the Public Health Service Act) 
10
from the application of any deductible pursuant 
11
to section 2799A–11(a)(1) of such Act, section 
12
726(a)(1) of the Employee Retirement Income 
13
Security Act of 1974, or section 9826(a)(1) of 
14
the Internal Revenue Code of 1986 shall not be 
15
considered when determining the actuarial value 
16
of a qualified health plan under this sub-
17
section.’’. 
18
(e) COVERAGE
OF CERTAIN INSULIN PRODUCTS 
19
UNDER CATASTROPHIC PLANS.—Section 1302(e) of the 
20
Patient Protection and Affordable Care Act (42 U.S.C. 
21
18022(e)) is amended by adding at the end the following: 
22
‘‘(4) COVERAGE
OF
CERTAIN
INSULIN
PROD-
23
UCTS.— 
24
23:20 Mar 02, 2022
H6833
11 
•HR 6833 IH
‘‘(A) IN GENERAL.—Notwithstanding para-
1
graph (1)(B)(i), a health plan described in 
2
paragraph (1) shall provide coverage of selected 
3
insulin products, in accordance with section 
4
2799A–11 of the Public Health Service Act, for 
5
a plan year before an enrolled individual has in-
6
curred cost-sharing expenses in an amount 
7
equal to the annual limitation in effect under 
8
subsection (c)(1) for the plan year. 
9
‘‘(B) TERMINOLOGY.—For purposes of 
10
subparagraph (A)— 
11
‘‘(i) the term ‘selected insulin prod-
12
ucts’ has the meaning given such term in 
13
section 2799A–11(b) of the Public Health 
14
Service Act; and 
15
‘‘(ii) the requirements of section 
16
2799A–11 of such Act shall be applied by 
17
deeming each reference in such section to 
18
‘individual health insurance coverage’ to be 
19
a reference to a plan described in para-
20
graph (1).’’. 
21
SEC. 3. APPROPRIATE COST-SHARING FOR CERTAIN INSU-
22
LIN PRODUCTS UNDER MEDICARE PART D. 
23
(a) IN GENERAL.—Section 1860D–2 of the Social 
24
Security Act (42 U.S.C. 1395w–102) is amended— 
25
23:20 Mar 02, 2022
H6833
12 
•HR 6833 IH
(1) in subsection (b)— 
1
(A) in paragraph (1)(A), by striking ‘‘The 
2
coverage’’ and inserting ‘‘Subject to paragraph 
3
(8), the coverage’’; 
4
(B) in paragraph (2)(A), by striking ‘‘and 
5
(D)’’ and inserting ‘‘and (D) and paragraph 
6
(8)’’; 
7
(C) in paragraph (3)(A), by striking ‘‘and 
8
(4)’’ and inserting ‘‘(4), and (8)’’; 
9
(D) in paragraph (4)(A)(i), by striking 
10
‘‘The coverage’’ and inserting ‘‘Subject to para-
11
graph (8), the coverage’’; and 
12
(E) by adding at the end the following new 
13
paragraph: 
14
‘‘(8) TREATMENT OF COST-SHARING FOR CER-
15
TAIN INSULIN PRODUCTS.— 
16
‘‘(A) IN GENERAL.—For plan years begin-
17
ning on or after January 1, 2023, the following 
18
shall apply with respect to insulin products (as 
19
defined in subparagraph (B)): 
20
‘‘(i) NO
APPLICATION
OF
DEDUCT-
21
IBLE.—The deductible under paragraph 
22
(1) shall not apply with respect to such in-
23
sulin products. 
24
23:20 Mar 02, 2022
H6833
13 
•HR 6833 IH
‘‘(ii) APPLICATION
OF
COST-SHAR-
1
ING.— 
2
‘‘(I) PLAN YEAR 2023.—For plan 
3
year 2023, the coverage provides ben-
4
efits for such insulin products, regard-
5
less of whether an individual has 
6
reached the initial coverage limit 
7
under paragraph (3) or the out-of- 
8
pocket threshold under paragraph (4), 
9
with cost-sharing that is equal to the 
10
applicable copayment amount. 
11
‘‘(II) PLAN YEAR 2024 AND SUB-
12
SEQUENT
PLAN
YEARS.—For plan 
13
year 2024 and subsequent plan years, 
14
the coverage provides benefits for 
15
such insulin products, prior to an in-
16
dividual reaching the out-of-pocket 
17
threshold under paragraph (4), with 
18
cost-sharing that is equal to the appli-
19
cable copayment amount. 
20
‘‘(III) APPLICABLE
COPAYMENT 
21
AMOUNT.—For 
purposes 
of 
this 
22
clause, the term ‘applicable copayment 
23
amount’ means, with respect to an in-
24
sulin product under a prescription 
25
23:20 Mar 02, 2022
H6833
14 
•HR 6833 IH
drug plan or an MA–PD plan, an 
1
amount that is not more than $35. 
2
‘‘(B) INSULIN PRODUCT.—For purposes of 
3
this paragraph, the term ‘insulin product’ 
4
means an insulin product that is approved 
5
under section 505 of the Federal Food, Drug, 
6
and Cosmetic Act or licensed under section 351 
7
of the Public Health Service Act and marketed 
8
pursuant to such approval or licensure, includ-
9
ing any insulin product that has been deemed 
10
to be licensed under section 351 of the Public 
11
Health 
Service 
Act 
pursuant 
to 
section 
12
7002(e)(4) of the Biologics Price Competition 
13
and Innovation Act of 2009 and marketed pur-
14
suant to such section.’’; and 
15
(2) in subsection (c), by adding at the end the 
16
following new paragraph: 
17
‘‘(4) TREATMENT OF COST-SHARING FOR INSU-
18
LIN PRODUCTS.—The coverage is provided in accord-
19
ance with subsection (b)(8).’’. 
20
(b) CONFORMING AMENDMENTS TO COST-SHARING 
21
FOR LOW-INCOME INDIVIDUALS.—Section 1860D–14(a) 
22
of the Social Security Act (42 U.S.C. 1395w–114(a)) is 
23
amended— 
24
(1) in paragraph (1)— 
25
23:20 Mar 02, 2022
H6833
15 
•HR 6833 IH
(A) in subparagraph (D)(iii), by adding at 
1
the end the following new sentence: ‘‘For plan 
2
year 2023 and subsequent plan years, the co-
3
payment amount applicable under the preceding 
4
sentence to an insulin product (as defined in 
5
section 1860D–2(b)(8)(B)) furnished to the in-
6
dividual may not exceed the applicable copay-
7
ment amount for the product under the pre-
8
scription drug plan or MA–PD plan in which 
9
the individual is enrolled.’’; and 
10
(B) in subparagraph (E), by inserting the 
11
following before the period at the end ‘‘or under 
12
section 1860D–2(b)(8) in the case of an insulin 
13
product (as defined in subparagraph (B) of 
14
such section)’’; and 
15
(2) in paragraph (2)— 
16
(A) in subparagraph (D), by adding at the 
17
end the following new sentence: ‘‘For plan year 
18
2023 and subsequent plan years, the amount of 
19
the coinsurance applicable under the preceding 
20
sentence to an insulin product (as defined in 
21
section 1860D–2(b)(8)(B)) furnished to the in-
22
dividual may not exceed the applicable copay-
23
ment amount for the product under the pre-
24
23:20 Mar 02, 2022
H6833
16 
•HR 6833 IH
scription drug plan or MA–PD plan in which 
1
the individual is enrolled.’’; and 
2
(B) in subparagraph (E), by adding at the 
3
end the following new sentence: ‘‘For plan year 
4
2023, the amount of the copayment or coinsur-
5
ance applicable under the preceding sentence to 
6
an insulin product (as defined in section 
7
1860D–2(b)(8)(B)) furnished to the individual 
8
may not exceed the applicable copayment 
9
amount for the product under the prescription 
10
drug plan or MA–PD plan in which the indi-
11
vidual is enrolled.’’ 
12
(c) IMPLEMENTATION.—The Secretary shall imple-
13
ment this section for plan years 2023 and 2024 by pro-
14
gram instruction or otherwise. 
15
Æ 
23:20 Mar 02, 2022
H6833
